Key Segments:
By Analyte/Biomarker
-
ctDNA
-
cfDNA
-
CTCs
-
Exosomes/Extracellular Vesicles
-
Methylation/Fragmentomics Signatures
By Technology
-
NGS-Based Comprehensive Genomic Profiling
-
PCR/ddPCR
-
Fragmentomics/Methylation Analytics
-
Others
By Clinical Use Case
-
Therapy Selection
-
Treatment-Response Monitoring
-
MRD/Recurrence Surveillance
-
Early Detection/Screening
By End User
-
Independent Reference Laboratories
-
Hospitals
-
Oncology Clinics
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Analyte X Clinical Use Case)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Guardant Health, Roche, Thermo Fisher Scientific, Natera, Illumina, Agilent Technologies, Bio-Rad Laboratories, and Exact Sciences, among others.
Key opportunities include multi-analyte panel innovation, minimal residual disease testing expansion, reimbursement growth, and emerging-market molecular testing infrastructure development.
The market is driven by regulatory endorsement, expanding reimbursement coverage, rising lung cancer incidence, and increasing adoption of blood-based genomic profiling.
The ctDNA segment dominated the Lung Cancer Liquid Biopsy Market, accounting for approximately 61.80% market share in 2025.
The North America region dominated the Lung Cancer Liquid Biopsy Market in 2025 with a 43.90% share, driven by reimbursement coverage and advanced testing infrastructure.